Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245582 | 1.00 | ACE (0.56) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL16344004 | 1.00 | ACE (0.56) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL10756784 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL5033212 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL5036114 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL15649718 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL2635952 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL317272 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL21853572 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL2635949 | 0.98 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108135962-A | For the pharmaceutical preparation of oral delivery peptide medicament | 塞浦路迈德有限责任公司 | 2018-06-08 | — | — | CN | claimed |
| CN-106794252-A | Pharmaceutical formulations for oral delivery of peptide or protein drugs | 塞浦路迈德有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| CN-103458873-B | For the aminoacid of the fatty-acylation of oral peptide delivery | NOVO NORDISK A/S (DK) | 2016-04-13 | — | — | CN | claimed |
| CN-103458873-A | Fatty acid acylated amino acids for oral peptide delivery | NOVO NORDISK AS | 2013-12-18 | — | — | CN | claimed |
| CN-119156221-A | Improved oral pharmaceutical formulations of therapeutic peptides and proteins | 西普鲁梅有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118829647-A | Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof | 詹森药业有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024005163-A1 | ANTIBACTERIAL COMPOSITION | 株式会社キャスティングイン | 2024-01-04 | — | — | WO | disclosed |
| CN-116669710-A | Compositions of peptide inhibitors of interleukin-23 receptor | 詹森药业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116601139-A | N-acyl amino acid surfactant and derivatives thereof | 宝洁公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3192493-B1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO KK (JP) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023100257-A1 | MARINE BIODEGRADATION PROMOTER HAVING HYDROCARBON GROUP, AND MARINE BIODEGRADABLE COMPOSITION | 日清紡ホールディングス株式会社 | 2023-06-08 | — | — | WO | disclosed |
| EP-2870958-B1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO KK (JP) | 2023-04-12 | — | — | EP | disclosed |
| CN-104955472-A | Fatty acid acylated amino acids for growth hormone delivery | NOVO NORDISK HEALTHCARE AG | 2015-09-30 | — | — | CN | disclosed |
| CN-104661643-A | Humectant and cosmetic containing the same | AJINOMOTO KK | 2015-05-27 | — | — | CN | disclosed |
| EP-2870958-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20150111859-A1 | Moisturizer and Cosmetic Agent Containing Same | AJINOMOTO CO., INC. (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2832345-A1 | COSMETIC COMPOSITION | Ajinomoto Co., Inc. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20150010489-A1 | COSMETIC COMPOSITION | AJINOMOTO CO., INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| CN-104244919-A | Cosmetic composition | AJINOMOTO KK | 2014-12-24 | — | — | CN | disclosed |
| CN-103458873-A | Fatty acid acylated amino acids for oral peptide delivery | NOVO NORDISK AS | 2013-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111859-A1 | Moisturizer and Cosmetic Agent Containing Same | FFAR1, PHOSPHO1, FAR1 | ACE 2963/4885ACE2 3023/4885L3MBTL1 4755/4885 |
| US-20150010489-A1 | COSMETIC COMPOSITION | CUTA, TRPA1, MITF | ACE 158/4885ACE2 447/4885L3MBTL1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.